Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized treatment based on nasal clinical manifestations and histamine/leukotriene D4 in allergic rhinitis
ChiCTR-IPR-16008163Phase 4Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jan 2014
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of loratadine and montelukast in allergic rhinitis (AR) (3 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoints: Histamine levels and Leukotriene D4 levels. Started Jan 2014; status: completed.
02
Drugs
loratadinemontelukast
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on ChiCTR-IPR-16008163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-16008163.